KRAS and colorectal carcinoma: To investigate the role of SLC1A5 (ASCT2) in CRC cell lines with mutated KRAS, we introduced non-silencing siRNA and two different siRNAs targeting SLC1A5 (referred as siSLC1A5#1 and siSLC1A5#2) into CRC cell lines (Figure S2).